Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study

Simple item page
dc.contributor.authorKidd, LaCreis R
dc.contributor.authorJones, Dominique Z
dc.contributor.authorRogers, Erica N
dc.contributor.authorKidd, Nayla C
dc.contributor.authorBeache, Sydney
dc.contributor.authorRudd, James E
dc.contributor.authorRagin, Camille
dc.contributor.authorJackson, Maria
dc.contributor.authorMcFarlane-Anderson, Norma
dc.contributor.authorTulloch-Reid, Marshall
dc.contributor.authorMorrison, Seian
dc.contributor.authorBrock, Guy N
dc.contributor.authorBarve, Shirish S
dc.contributor.authorKimbro, Kevin S
dc.date.accessioned2014-04-11T13:24:55Z
dc.date.available2014-04-11T13:24:55Z
dc.date.issued2012-11-20
dc.date.updated2014-04-11T13:24:55Z
dc.description.abstractAbstract Background Chemokine and chemokine receptors play an essential role in tumorigenesis. Although chemokine-associated single nucleotide polymorphisms (SNPs) are associated with various cancers, their impact on prostate cancer (PCA) among men of African descent is unknown. Consequently, this study evaluated 43 chemokine-associated SNPs in relation to PCA risk. We hypothesized inheritance of variant chemokine-associated alleles may lead to alterations in PCA susceptibility, presumably due to variations in antitumor immune responses. Methods Sequence variants were evaluated in germ-line DNA samples from 814 African-American and Jamaican men (279 PCA cases and 535 controls) using Illuminaand#8217;s Goldengate genotyping system. Results Inheritance of CCL5 rs2107538 (AA, GA+AA) and rs3817655 (AA, AG, AG+AA) genotypes were linked with a 34-48% reduction in PCA risk. Additionally, the recessive and dominant models for CCR5 rs1799988 and CCR7 rs3136685 were associated with a 1.52-1.73 fold increase in PCA risk. Upon stratification, only CCL5 rs3817655 and CCR7 rs3136685 remained significant for the Jamaican and U.S. subgroups, respectively. Conclusions In summary, CCL5 (rs2107538, rs3817655) and CCR5 (rs1799988) sequence variants significantly modified PCA susceptibility among men of African descent, even after adjusting for age and multiple comparisons. Our findings are only suggestive and require further evaluation and validation in relation to prostate cancer risk and ultimately disease progression, biochemical/disease recurrence and mortality in larger high-risk subgroups. Such efforts will help to identify genetic markers capable of explaining disproportionately high prostate cancer incidence, mortality, and morbidity rates among men of African descent.
dc.description.versionPeer Reviewed
dc.identifier.citationHereditary Cancer in Clinical Practice. 2012 Nov 20;10(1):16
dc.identifier.urihttp://dx.doi.org/10.1186/1897-4287-10-16
dc.identifier.urihttps://hdl.handle.net/2139/38056
dc.language.rfc3066en
dc.rights.holderLaCreis R Kidd et al.; licensee BioMed Central Ltd.
dc.titleChemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study
dc.typeJournal Article

Files

Original bundle
Now showing 1 - 5 of 5
No Thumbnail Available
Name:
1897-4287-10-16.xml
Size:
147.58 KB
Format:
Extensible Markup Language
Download
Thumbnail Image
Name:
1897-4287-10-16.pdf
Size:
228.72 KB
Format:
Adobe Portable Document Format
Download
No Thumbnail Available
Name:
1897-4287-10-16-S3.DOC
Size:
73 KB
Format:
Microsoft Word
Download
No Thumbnail Available
Name:
1897-4287-10-16-S2.DOC
Size:
33.5 KB
Format:
Microsoft Word
Download
No Thumbnail Available
Name:
1897-4287-10-16-S1.DOC
Size:
34.5 KB
Format:
Microsoft Word
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

BioMed Central